Biosimilars: Design and analysis of follow-on biologics

Biosimilars: Design and Analysis of Follow-on Biologics

Volumn , Issue , 2013, Pages 1-411

  Chow, Shein Chung ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054711441     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b15303     Document Type: Book

References (262)

1. Aitchison, J. and Dunsmore, I.R. (1975). Statistical Prediction Analysis. Cambridge University Press, New York.
2. Anderson, S. and Hauck, W.W. (1990). Consideration of individual bioequivalence. J. Pharmacokinet. Biopharm., 18, 259–273.
3. Arnold, B. and Groeneveld, R. (1979). Bound on expectations of linear systematic statistics based on dependent samples. Ann. Statist., 7, 220–223.
4. Berger, R.L. (1982). Multiparametric hypothesis testing and acceptance sampling. Technometrics, 24, 295–300.
5. Boddy, A.W., Snikeris, F.C., Kringle, R.O., Wei, G.C.G., Opperman, J.A., and Midha, K.K. (1995). An approach for widening the bioequivalence limits in the case of highly variable drugs. Pharm. Res., 12, 1865–1868.
6. Box, G.E.P. and Tiao, G.C. (1973). Bayesian Inference in Statistical Analysis. Addison-Wesley, Reading, MA.
7. Brown, M.B. and Forsythe, A.B. (1974). Robust tests for the equality of variances. J. Am. Statist. Assoc., 69, 364–367.
8. Carrasco, J.L. and Jover, L. (2003). Assessing individual bioequivalence using structural equation model. Stat. Med, 22, 901–912.
9. Carstenson, J.T., Franchini, M., and Ertel, K. (1992). Statistical approaches to stability protocol design. J. Pharm. Sci., 81, 303–308.
10. Casella, G. and Berger, R. (2002). Statistical Inference, 2nd edn. Duxbury, Pacific Grove, CA.
11. CBER/FDA. (1993). Points to consider in the characterization of cell lines to produce biologicals. Center for Biologic Evaluation and Research, Food and Drug Administration, Rockville, MD.
12. CBER/FDA. (1999). Summary of CBER Considerations on Selected Aspects of Active Controlled Trial Design and Analysis for the Evaluation of Thrombolytics in Acute MI, Center for Biological Evaluation and Research, Food and Drug Administration, Rockville, MD.
13. CD. (2003). Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Off. J. Eur. Union L 159/46.
14. Chen, B.L. (2009). CMC issues and regulatory requirements for biosimilars. Trends Bio/Pharm. Ind., 5, 19–26.
15. Chen, C. (1996). FDA’s views on bracketing and matrixing. EFPIA Symposium: Advanced Topics in Pharmaceutical Stability Testing—Building in the ICH Guideline, Brussels, Belgium, October 1996.
16. Chen, K.W., Chow, S.C., and Li, G. (1997). A note on sample size determination for bioequivalence studies with higher-order crossover designs. J. Pharm. Biopharm., 25, 753–765.
17. Chen, K.W., Li, G., Sun, Y., and Chow, S.C. (1996). A confidence region approach for assessing equivalence in variability of bioavailability. Biom. J., 4, 475–487.
18. Chen, M.L. (1995). Individual bioequivalence. Invited Presentation at International Workshop: Statistical and Regulatory Issues on the Assessment of Bioequivalence, Dusseldorf, Germany, October 19–20, 1995.
19. Chen, M.L. (1997). Individual bioequivalence—A regulatory update. J. Biopharm. Stat., 7, 5–11.
20. Chen, M.L., Shah, V., Patnaik, R., Adams, W., Hussain, A., Conner, D., Mehta, M., Malinowski, H., Lazor, J., Huang, S.M., Hare, D., Lesko, L., Sporn, D., and Williams, R. (2001). Bioavailability and bioequivalence: A FDA regulatory overview. Pharm. Res., 18, 1645–1650.
21. Chinchilli, V.M. and Esinhart, J.D. (1996). Design and analysis of intra-subject variability in cross-over experiments. Stat. Med., 15, 1619–1634.
22. Chirino, A.J. and Mire-Sluis, A. (2004). Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol., 22, 1383–1391.
23. Chiu, S.T., Chen, C., Chow, S.C., and Chi, E. (2013). Assessing biosimilarity using the method of generalized Pivotal quantities. Generics Biosimilars Initiatives to appear.
24. Chow, S.C. (1988). A new procedure for the estimation of variance components. Stat. Prob. Lett., 6, 349–355.
25. Chow, S.C. (1992). Statistical design and analysis of stability studies. Proceedings of the 48th Annual Conference on Applied Statistics, Atlantic City, NJ, 1992.
26. Chow, S.C. (1999). Individual bioequivalence-A review of the FDA draft guidance. Drug Inf. J., 33, 435–444.
27. Chow, S.C. (2007). Statistical Design and Analysis of Stability Studies, Chapman and Hall/CRC Press/Taylor & Francis Group, New York.
28. Chow, S.C. (2010). On Scientific factors of biosimilarity and interchangeability. Presented at FDA Public Hearing on Approval Pathway for Biosimilar and Interchangeable Biological Products. Silver Spring, MD, November 2–3, 2010.
29. Chow, S.C. (2011). Quantitative evaluation of bioequivalence/biosimilarity. J. Bioequiv. Bioavailab., Suppl. 1-002, 1–8, http://dx.doi.org/10.4172/jbbs1-002.
30. Chow, S.C. (2013). Assessing biosimilarity and drug interchangeability of biosimilar products. Stat. Med., 32, 361–363.
31. Chow, S.C., Endrenyi, L., and Lachenbruch, P.A. (2013a). Comments on FDA draft guidances on biosimilar products. Stat. Med., 32, 364–369.
32. Chow, S.C., Endrenyi, L., Lachenbruch, P.A., Yang, L.Y., and Chi, E. (2011). Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. Biosimilars, 1, 13–26.
33. Chow, S.C., Hsieh, T.C., Chi, E., and Yang, J. (2010a). A comparison of moment-based and probability-based criteria for assessment of follow-on biologics. J. Biopharm. Stat., 20, 31–45.
34. Chow, S.C., Lu, Q., Tse, S.K., and Chi, E. (2010b). Statistical methods for assessment of biosimilarity using biomarker data. J. Biopharm. Stat., 20, 90–105.
35. Chow, S.C., Shao, J., and Ho, H.C. (2000). Statistical analysis for placebo-challenging design in clinical trials, Stat. Med., 19, 1029–1037.
36. Chow, S.C., Shao, J., and Li, L. (2004). Assessing bioequivalence using genomic data. J. Biopharm. Stat., 14, 869–880.
37. Chow, S.C., Shao, J., and Wang, H. (2002). Individual bioequivalence testing under 2 × 3 crossover designs. Stat. Med., 21, 629–648.
38. Chow, S.C., Shao, J., and Wang, H. (2008). Sample Size Calculation in Clinical Research, 2nd edn., Chapman & Hall/CRC Press/Taylor & Francis Group, New York.
39. Chow, S.C., Wang, J., Endrenyi, L., and Lachenbruch, P.A. (2013b). Scientific considerations for assessing biosimilar products. Stat. Med., 32, 370–381.
40. Chow, S.C., Yang, L.Y., Starr, A, and Chiu, S.T. (2013c). Statistical methods for assessing interchangeability of biosimilars. Stat. Med., 32, 442–448.
41. Chow, S.C. and Chang, M. (2011). Adaptive Design Methods in Clinical Trials, 2nd edn., Chapman and Hall/CRC Press/Taylor & Francis Group, New York.
42. Chow, S.C. and Chiu, S.T. (2013). Sample size and data monitoring for clinical trials with extremely low incidence rate. Therapeutic Innovation of Regulatory Science, In press.
43. Chow, S.C. and Ki, F. (1997). Statistical comparison between dissolution profiles of drug products. J. Biopharm. Stat., 7, 241–258.
44. Chow, S.C. and Liu, J.P. (1995). Statistical Design and Analysis in Pharmaceutical Science. Marcel Dekker, Inc., New York.
45. Chow, S.C. and Liu, J.P. (1997). Meta-analysis for bioequivalence review. J. Biopharm. Stat., 7, 97–111.
46. Chow, S.C. and Liu, J.P. (2008). Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd edn. Chapman and Hall/CRC Press/Taylor & Francis Group, New York.
47. Chow, S.C. and Liu, J.P. (2010). Statistical assessment of biosimilar products. J. Biopharm. Stat., 20, 10–30.
48. Chow, S.C. and Shao, J. (1991). Estimating drug shelf-life with random batches. Biometrics, 47, 1071–1079.
49. Chow, S.C. and Shao, J. (1997). Statistical methods for two-sequence dual crossover designs with incomplete data. Stat. Med., 16, 1031–1039.
50. Chow, S.C. and Shao, J. (1999). Bioequivalence review for drug interchangeability. J. Biopharm. Stat., 9, 485–497.
51. Chow, S.C. and Shao, J. (2002a). Statistics in Drug Research. Marcel Dekker, Inc., New York.
52. Chow, S.C. and Shao, J. (2002b). A note on statistical methods for assessing therapeutic equivalence. Controll. Clin. Trials, 23, 515–520.
53. Chow, S.C. and Shao, J. (2006). On non-inferiority margin and statistical test in active control trials. Stat. Med., 25, 1101–1113.
54. Chow, S.C. and Tse, S.K. (1990). A related problem in bioavailability/bioequivalence studies—Estimation of intrasubject variability with a common CV. Biomet. J., 32, 597–607.
55. Chow, S.C. and Tse, S.K. (1991). On the estimation of total variability in assay validation. Stat. Med., 10, 1543–1553.
56. Church, J.D. and Harris, B. (1970). The estimation of reliability from stress–strength relationships. Technometrics, 12, 49–54.
57. Conover, W.J. (1973). Rank tests for one sample, two samples, and k samples without the assumption of a continuous distribution function. Ann. Stat., 1, 1105–1125.
58. Conover, W.J. (1999). Practical Nonparametric Statistics, 3rd edn., Wiley, New York.
59. Cornell, R.G. (1990). The evaluation of bioequivalence using nonparametric procedures. Commun. Stat.: Theory Methods, 19, 4153–4169.
60. CPMP. (1997). Reduced stability testing plan—Bracketing and matrixing. CPMP/ QWP/157/96. London, U.K.
61. CPMP. (2001). Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMEA/CPMP/3097/02/Final8. London, U.K.
62. Crommelin, D., Bermejo, T., Bissig, M., Damianns, J., Kramer, I., Rambourg, P., Scroccaro, G., Strukelj, B., Tredree, R., and Ronco, C. (2005). Biosimilars, generic versions of the first generation of therapeutic proteins: Do they exist? Contrib. Nephrol., 149, 287–294.
63. David, H. (1981). Order Statistics. Wiley, New York.
64. David, H. and Nagaraja, H. (2003). Order Statistics. John Wiley & Sons, New York.
65. Davis, G.C., Beals, J.M., Johnson, C., Mayer, M.H., Meiklejohn, B.I., Mitlak, B.H., Roth, J.L., Towns, J.K., and Veenhuizen, M. (2009). Recommendations regarding technical standards for follow-on biologics: Comparability, similarity, interchangeability. Curr. Med. Res. Opin., 25, 1655–1661.
66. Davit, B.M., Conner, D.P., Fabian-Fritsch, B. et al. (2008). Highly variable drugs: Observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J, 10, 148–156.
67. De Weck, A.L. (1974). Low molecular weight antigens. In: The Antigens, Vol. 2, Sela, M., Ed. Academic Press, New York, pp. 141–248.
68. DeWoody, K. and Raghavarao, D. (1997). Some optimal matrix designs in stability studies. J. Biopharm. Stat., 7, 205–213.
69. Dragalin, V., Fedorov, V., Patterson, S. et al. (2003). Kullback-Leibler divergence for evaluating bioequivalence. Stat. Med., 22, 913–930.
70. Edwards, W., Lindman, H., and Savage, L.J. (1963). Bayesian statistical inference for psychological research. Psycol. Rev., 70, 193.
71. EMA. (2001). Note for guidance on the investigation of bioavailability and bioequivalence. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/EWP/QWP/1401/98, London, U.K.
72. EMA. (2003a). Note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance—Non clinical and clinical issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/3097/02, London, U.K.
73. EMA. (2003b). Rev. 1 guideline on comparability of medicinal products containing biotechnology-derived proteins as drug substance—Quality issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/ CHMP/BWP/3207/00/Rev 1, London, U.K.
74. EMA. (2006a). Guideline on similar biological medicinal products. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/ CHMP/437/04, London, U.K.
75. EMA. (2006b). Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as drug substance: Quality issues. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/ CHMP/49348/05, London, U.K.
76. EMA. (2006c). Draft annex guideline on similar biological medicinal products containing biotechnology-derived proteins as drug substance—Non clinical and clinical issues—Guidance on biosimilar medicinal products containing recombinant erythropoietins. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/94526/05, London, U.K.
77. EMA. (2006d). Draft annex guideline on similar biological medicinal products containing biotechnology-derived proteins as drug substance—Non clinical and clinical issues—Guidance on biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/31329/05, London, U.K.
78. EMA. (2006e). Draft annex guideline on similar biological medicinal products containing biotechnology-derived proteins as drug substance—Non-clinical and clinical issues—Guidance on biosimilar medicinal products containing somat-ropin. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/94528/05, London, U.K.
79. EMA. (2006f). Draft annex guideline on similar biological medicinal products containing biotechnology-derived proteins as drug substance—Non clinical and clinical issues—Guidance on biosimilar medicinal products containing recombinant human insulin. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/32775/05, London, U.K.
80. EMA. (2006g). Guideline on the clinical investigating of the pharmacokinetics of therapeutic proteins. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/89249/04, London, U.K.
81. EMA. (2006h). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMEA/CHMP/BMWP/42832, London, U.K.
82. EMA. (2007). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. The European Medicines Agency Evaluation of Medicines for Human Use. EMEA/CHMP/MWP/14327/2006, London, U.K.
83. EMA. (2009a). Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. EMEA/CHMP/BMWP/118264/2007. London, U.K., 19 March.
84. EMA. (2009b). Non-clinical and clinical development of similar medicinal products containing recombinant interferon alfa. EMEA/CHMP/BMWP/102046/06, London, U.K.
85. EMA. (2010a). Draft guideline on similar biological medicinal products containing monoclonal antibodies. EMA/CHMP/BMWP/403543/2010, London, U.K.
86. EMA. (2010b). Concept paper on similar biological medicinal products containing recombinant follicle stimulation hormone. EMA/CHMP/BMWP/94899/2010, London, U.K.
87. EMA. (2010c). Guideline on the investigation of bioequivalence. CPMP/EWP/ QWP/1401/98 Rev. 1/Corr, London, U.K.
88. EMA. (2011a). Concept paper on the revision of the guideline on similar biological medicinal product. EMA/CHMP/BMWP/572643, London, U.K.
89. EMA. (2011b). Concept paper on the revision of the guideline on similar biological medicinal products contain biotechnology-derived proteins as active substance: Quality issues. EMEA/CHMP/BWP/617111, London, U.K.
90. EMA. (2011c). Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMEA/CHMP/BMWP/572828, London, U.K.
91. EMA. (2011d). Guideline on similar biological medicinal products containing interferon beta. EMA/CHMP/BMWP/652000/2010, London, U.K.
92. Endrenyi, L., Chang, C., Chow, S.C., and Tothfalusi, L. (2013). On the interchangeability of biologic drug products. Stat. Med., 32, 434–441.
93. max for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharm. Ther. Toxicol., 29, 394–399.
94. Endrenyi, L. and Tothfalusi, L. (2009). Regulatory and study conditions for the determination of bioequivalence of highly variable drugs. J. Pharm. Pharm. Sci., 12, 138–149.
95. Enis, P. and Geisser, S. (1971). Estimation of the probability that Y < X. J. Am. Stat. Assoc., 66, 162–168.
96. Fairweather, W.R., Lin, T.D., and Kelly, R. (1994). Regulatory and design aspects of complex stability studies. Proceedings of the Biostatistics Subsection/Clinical Data Management Group of Pharmaceutical Research and Manufacturers of America, Washington, DC, October 1994.
97. Fairweather, W.R., Lin, T.D., and Kelly, R. (1995). Regulatory, design, and analysis aspects of complex stability studies. J. Pharm. Sci., 84, 1322–1326.
98. FDA. (1987). Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics. Center for Drugs and Biologics, Office of Drug Research and Review, Food and Drug Administration, Rockville, MD.
99. FDA. (1988). Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Application. U.S. Food and Drug Administration, Rockville, MD.
100. FDA. (1992). Guidance on Statistical Procedures for Bioequivalence Using a Standard Two-treatment Crossover Design. Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
101. FDA. (1996). FDA guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnology-derived products, the U.S. Food and Drug Administration, Rockville, MD.
102. FDA. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. The U.S. Food and Drug Administration, Rockville, MD.
103. FDA. (1998). Data sets of bioequivalence for individual and population bioequivalence. www.fda.gov/cder/bioeuivdata/index.htm.
104. FDA. (1999). Guidance for Industry on Nasal Spray and Inhalation Solution, Suspension and Spray Drug Products. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD.
105. FDA. (2001). Guidance on statistical approaches to establishing bioequivalence. Center for Drug Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
106. FDA. (2002). Guidance for industry—Immunotoxicology evaluation of investiga-tional new drugs. Center for Drug Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
107. FDA. (2003). Guidance on bioavailability and bioequivalence studies for orally administrated drug products—General considerations. Center for Drug Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
108. FDA. (2004). Guidance for Industry—Botanical Drug Products. The United States Food and Drug Administration, Rockville, MD.
109. FDA. (2005). Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process. The U.S. Food and Drug Administration, Rockville, MD.
110. FDA. (2010). Guidance for industry—Non-inferiority clinical trials. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Siler Spring, MD.
111. FDA. (2012a). Scientific considerations in demonstrating biosimilarity to a reference product. The U.S. Food and Drug Administration, Silver Spring, MD.
112. FDA. (2012b). Quality considerations in demonstrating biosimilarity to a reference protein product. The U.S. Food and Drug Administration, Silver Spring, MD.
113. FDA. (2012c). Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. The U.S. Food and Drug Administration, Silver Spring, MD.
114. Fieller, E. (1954). Some problems in interval estimation. J. R. Stat. Soc., Series B, 16, 175–185.
115. Finney, D.J. (1979). Statistical Method in Biological Assay, 3rd edn. Oxford University Press, New York.
116. Fleming, T.R. (2000). Design and interpretation of equivalence trials. Am. Heart J., 139, S172–S176.
117. Fox, A. (2010). Biosimilar medicines—New challenges for new class of medicine. J. Biopharm. Stat., 20, 1–9.
118. GaBI Online. (2012a). Generics and biosimilars initiative. Generics grab 80% share of US market and fill 78% of prescriptions [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International. www.gabionline.net/Reports/ Generics-grab-80-share-of-US-marketand-fill-78-of-prescriptions. Accessed on March 23, 2012.
119. GaBI Online. (2012b). Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International. www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed on March 23, 2012.
120. Goodman, S.N. (1992). A common on replication, p-values and evidence. Stat. Med., 11, 875–879.
121. Gould, A.L. (1995). Group sequential extensions of Standard bioequivalence testing procedure. J. Pharmacokinet. Biopharm., 23, 57–85.
122. GPhA. (2004). Biopharmaceuticals (follow-on protein products): Scientific considerations for an abbreviated approval pathway. Generic Pharmaceutical Association, December 8, 2004. Docket No. 2004N-0355 Scientific Considerations Related to Developing Follow-on Protein Products, U.S. Food and Drug Administration, Rockville, MD.
123. Graybill, F. and Wang, C.M. (1980). Confidence intervals on nonnegative linear combinations of variances. J. Am. Stat. Assoc., 75, 869–873.
124. Gumbel, E.J. (1954). The maxima of the mean largest value and of the range. Ann. Math. Statist., 25, 76–84.
125. Haidar, S.H., Davit, B.M., Chen, M.L. et al. (2008). Bioequivalence approaches for highly variable drugs and drug products. Pharm. Res., 25, 237–241.
126. Haidar, S.H., Makhlouf, F., Schuirmann, D.J., Hyslop, T., Davit, B., Conner, D., and Yu, L.X. (2008). Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J., 10, 450–454.
127. Hartley, H.O. and David, H.A. (1954). Universal bounds for mean range and extreme observation. Ann. Math. Statist., 25, 85–99.
128. Hauschke, D., Steinijans, V.W., Diletti, E., and Burke, W. (1992). Sample size determination for bioequivalence assessment using a multiplicative model. J. Pharmacokinet. Biopharm., 20, 557–581.
129. Hauschke, D., Steinijians, V.W., and Diletti, E. (1990). A distribution-free procedure for the statistical analyses of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol., 28, 72–78.
130. Health Canada. (1992). Guidance for industry: Conduct and analysis of bioavailability and bioequivalence studies—Part A: Oral dosage formulation used for systemic effects. Ottawa, Ontario, Canada.
131. Health Canada. (2006). Guidance for Industry, Bioequivalence Requirements: Critical Dose Drugs. Health Canada, Ottawa, Ontario, Canada.
132. Health Canada. (2010). Guidance for sponsors: Information and submission requirements for subsequent entry biologics (SEBs). Ottawa, Ontario, Canada.
133. Health Canada. (2012). Guidance document: Comparative bioavailability standards: Formulations used for systemic effects. Ottawa, Ontario, Canada.
134. Helboe, P. (1992). New designs for stability testing programs: Matrix or factorial designs. Authorities’ viewpoint on the predictive value of such studies. Drug Inform. J., 26, 629–634.
135. Howe, W.G. (1974). Approximate confidence limits on the mean of X + Y where X and Y are two tabled independent random variables. J. Am. Stat. Assoc., 69, 789–794.
136. Hsieh, T.C., Chow, S.C., Liu, J.P., Hsiao, C.F., and Chi, E. (2010). Statistical test for evaluation of biosimilarity of follow-on biologics. J. Biopharm. Stat., 20, 20, 75–89.
137. Hsieh, T.C., Chow, S.C., Yang, L.Y., and Chi, E. (2013). The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics. Stat. Med., 32, 406–414.
138. Hung, H.M.J., Wang, S.J., Tsong, Y., Lawrence, J., and O’Neil, R.T. (2003). Some fundamental issues with non-inferiority testing in active controlled trials. Stat. Med., 22, 213–225.
139. Hyslop, T., Hsuan, F., and Holder, K.J. (2000). A small-sample confidence interval approach to assess individual bioequivalence. Stat. Med., 19, 2885–2897.
140. ICH. (1993). Stability testing of new drug substances and products. Tripartite International Conference on Harmonization Guideline, Q1A, Geneva, Switzerland.
141. ICH. (1996). Q5C guideline on quality of biotechnological products: Stability testing of biotechnological/biological products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
142. ICH. (1997). Guidance for industry—S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
143. ICH. (1998). E5 guideline on ethnic factors in acceptability of foreign data. The U.S. Federal Register, 83, 31790–31796.
144. ICH. (1999). Q6B guideline on test procedures and acceptance criteria for biotechnological/biological products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
145. ICH. (2000). Guideline E-10. International Conference on Harmonization Guideline: Guidance on choice of control group and related design and conduct issues in clinical trials. Food and Drug Administration, DHHS, Rockville, MD.
146. ICH. (2003). Guidance for industry. Q1A(R2) stability testing of new drug substances and products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD, November 2003.
147. ICH. (2003). Guidance for industry. Q1D bracketing and matrixing designs for stability testing of new drug substances and products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD, November 2003.
148. ICH. (2004). Guidance for industry. Q1E evaluation of stability data. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD, June 2004.
149. ICH. (2005). Q5E guideline on comparability of biotechnological/biological products subject to changes in their manufacturing process. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, the U.S. Food and Drug Administration, Rockville, MD.
150. Ju, H.L. and Chow, S.C. (1995). On stability designs in drug shelf-life estimation. J. Biopharm. Stat., 5, 210–214.
151. Kang, S.H. and Chow, S.C. (2013). Statistical assessment of biosimilarity based on relative distance between follow-on biologics. Stat. Med., 32, 382–392.
152. Karalis, V., Symillides, M., and Macheras, P. (2004). Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharm. Res., 21, 1933–1942.
153. Karalis, V., Symillides, M., and Macheras, P. (2004). Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharm. Res., 21, 1933–1942.
154. Kendrick, B.S., Chrimes, G., Cockrill, S.L., Gabrielson, J.P., Arthur, K.K. et al. (2009). Comparability of biotechnological/biological products subject to changes in their manufacturing. BioPharm Int., 22, 32–44.
155. KFDA. (2011). Korean guidelines on the evaluation of similar biotherapeutic products (SBPs). Korean Food and Drug Administration, South Korea.
156. Kimber, I., Kerkvliet, N.I., Taylor, S.L., Astwood, J.D., Sarlo, K., and Dearman, R.J. (1999). Toxicology of protein allergenicity: Prediction and characterization. Toxicol. Sci., 48, 157–162.
157. Korn, E.L., Albert, P.S., and McShane, L.M. (2005). Assessing surrogated as trial end-points using mixed models, Stat. Med., 24, 163–182.
158. Kozlowski, S. (2007). FDA policy on follow on biologics. Proceedings of the Biosimilars 2007, George Washington University, Washington, DC.
159. Kuhlmann, M. and Covic, A. (2006). The protein science of biosimilars. Nephrol. Dial. Transplant., 21, Suppl 5: v4–v8.
160. Lanthier, M., Behrman, R., and Nardinelli, C. (2008). Economic issues with follow-on protein products. Nat. Rev. Drug Discov., 7, 733–737.
161. Laster, L.L. and Johnson, M.F. (2003). Non-inferiority trials: the ‘at least as good as’ criterion. Stat. Med., 22, 187–200.
162. Lee, M.S., Chen, M.C., Liao, Y.C., and Hsiung, A.G. (2007). Identifying potential immunodominant positions and predicting antigenic variants of influenza A/H3N2 viruses. Vaccine, 25, 8133–8139.
163. Lee, M.S. and Chen, M.C. (2004). Predicting antigenic variants of influenza A/H3N2 viruses. Emerg. Infect. Dis., 10, 1385–1390.
164. Lee, Y., Shao, J., and Chow, S.C. (2004). Modified large-sample confidence intervals for linear combinations of variance components: Extension, theory, and application. J. Am. Stat. Assoc., 99, 467–478.
165. Lee, Y., Shao, J., Chow, S.C., and Wang, H. (2002). Test for inter-subject and total vari-abilities under crossover designs. J. Biopharm. Stat., 12, 503–534.
166. Leeson, L.J. (1995). In vitro/in vivo correlation. Drug Inform. J., 29, 903–915.
167. Lei, L. and Olson, K. (2010). Evaluating statistical methods to establish clinical similarity of two biologics. J. Biopharm. Stat., 20, 62–74.
168. Levene, H. (1960). Robust tests for the equality of variances. In: Contributions to Probability and Statistics. Olkin, I., Ed. Stanford University Press, Palo Alto, CA, pp. 278–292.
169. Levy, N.W. (1986). Bioequivalence of Solid oral dosage forms. A presentation to the U.S. Food and Drug Administration Heaving on Bioequivalence of Solid Oral Dosage Forms, September 29–October 1, Pharmaceutical Manufacturer Association, Section II, pp. 9–11.
170. Li, Y., Liu, Q., Wood, P., and Johri, A. (2013). Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins. Stat. Med., 32, 393–405.
171. Liang, B.A. (2007). Regulating follow-on biologics. Harvard J. Legis., 44, 363–373.
172. Liao, J.J.Z. and Darken, P.F. (2013). Comparability of critical quality attributes for establishing biosimilarity. Stat. Med., 32, 462–469.
173. Liao, J.J.Z and Heyse, J.F. (2011). Biosimilarity for follow-on biologics. Stat. Biopharm. Res., 3, 445–455.
174. Liao, Y.C., Lee, M.S., Ko, C.Y., and Hsiung, C.A. (2008). Bioinformatics models for predicting variants of influenza A/H3N2 viruses. Bioinformatics, 24, 505–512.
175. Lin, D. (1997). Stability studies at the FDA. PERI Course: Non-Clinical Statistics for Drug Discovery and Development, Arlington, VI, March 1997.
176. Lin, J.R., Chow, S.C., Chang, C.H., Lin, Y.C., and Liu, J.P. (2013). Application of the parallel line assay to assessment of biosimilar products based on binary end-points. Stat. Med., 32, 449–461.
177. Lin, T.D. (1994). Applicability of matrix and bracket approach to stability study design. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 142–147.
178. Lindley, D.V. (1965). Introduction to Probability and Statistics for a Bayesian Viewpoint, Part II Inference. Cambridge University Press, Cambridge, U.K.
179. Liu, J.P. (1998). Statistical evaluation of individual bioequivalence. Commun. Stat.: Theory Methods, 27, 1433–1451.
180. Liu, J.P., Lin, J.R., and Chow, S.C. (2009). Inference on treatment effects for targeted clinical trials under enrichment design. Pharm. Stat., published on line. DOI: 10.1002/pst.364.
181. Liu, J.P. and Chow, S.C. (1992). On assessment of bioequivalence in variability of bioavailability. Comm. Stat. Theory Methods, 21, 2591–2608.
182. Liu, J.P. and Chow, S.C. (2008). Statistical issues on the diagnostic multivariate index assay and targeted clinical trials, J. Biopharm. Stat., 18, 167–182.
183. Liu, J.P. and Lin, J.R. (2008). Statistical methods for targeted clinical trials under enrichment design. J. Formosan Med. Assoc., 107, S34–S41.
184. Liu, J.P. and Weng, C.S. (1992). Estimation of direct formulation effect under log-normal distribution in bioavailability/bioequivalence studies. Stat. Med., 11, 881–896.
185. Liu, J.P. and Weng, C.S. (1994). Estimation of log-transformation in assessing bioequivalence. Comm. Stat. Theory Methods, 23, 421–434.
186. Liu, J.P. and Weng, C.S. (1995). Bias of two one-sided tests procedures in assessment of bioequivalence. Stat. Med., 14, 853–861.
187. 2 as a criterion for assessment of similarity between dissolution profiles. Drug Inf. J., 31, 1255–1271.
188. Los, M., Roodhart, J.M., and Voest, E.E. (2007). Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist, 12, 443–450.
189. Lu, Q., Chow, S.C., and Tse, S.K. (2007). Statistical quality control process for traditional Chinese medicine with multiple correlative components. J. Biopharm. Stat., 17, 791–808.
190. Lu, Q., Tse, S.K., Chow, S.C., and Yang, J. (2009). On assessing bioequivalence using genomic data with model misspecification. J. Biopharm. Stat., 19, 571–579.
191. Ma, M.C., Lin, R.P., and Liu, J.P. (1999). Statistical evaluation of dissolution similarity. Stat. Sin., 9, 1011–1027.
192. Mann, H.B. and Whitney, D.R. (1947). On a test of whether one or two random variables is stochastically larger than the other. Ann. Math. Stat., 18, 50–60.
193. Markovic, I. (2007). Chemistry, manufacturing and control issues in production of therapeutic biologic protein products. Presented at NCI Biological Resources Branch Workshop “Working with FDA: Biological Products and Clinical Development”. National Cancer Institute, Bethesda, MD.
194. Markovic, I. (2009). Chemistry, manufacturing and control issues in production of therapeutic biologic protein products. Proceedings of the Working with FDA: Biological Products and Clinical Development, Rockville, MD.
195. McCamish, M. and Woollett, G. (2011). Worldwide experience with biosimilar development. mAbs, 3, 209–217.
196. MHLW. (2009). Guidelines for the quality, safety and efficacy assurance of follow-on biologics (Yakushoku shinsahatu 0304007). Japan.
197. Moore, J.W. and Flanner, H.H. (1996). Mathematical comparison of curves with an emphasis on dissolution profiles. Pharm. Technol., 20, 64–74.
198. Morgan, W.A. (1939). A test for the significance of the difference between the two variances in a sample from a normal bivariate population. Biometrika, 31, 13–19.
199. Murphy, J.R. (1996). Uniform matrix stability study designs. J. Biopharm. Stat., 6, 477–494.
200. Nordbrock, E. (1989). Statistical study design. Proceedings of the National Stability Discussion Group; October 1989, Washington, DC.
201. Nordbrock, E. (1991). Statistical comparison of NDA stability study designs. Proceedings of the Midwest Biopharmaceutical Statistics Workshop, Chelsea, MI, May 1991.
202. Nordbrock, E. (1992). Statistical comparison of stability study designs. J. Biopharm. Stat.. 2, 91–113.
203. Nordbrock, E. (1994a). Computing power details. PERI: Training Course in Non-Clinical Statistics, Dallas, TX, February 1994.
204. Nordbrock, E. (1994b). Design and analysis of stability studies. Proceedings of the Biopharmaceutical Section of the American Statistical Association, Alexandria, VA, pp. 291–294.
205. Nordbrock, E. (1994c). Statistically designed stability studies, an industry perspective. Proceedings of the Biostatistics Subsection/Clinical Data Management Group of Pharmaceutical Research and Manufacturers of America, Washington, DC, October 1994.
206. Nordbrock, E. (2003). Stability matrix designs. In Encyclopedia of Biopharmaceutical Statistics, 2nd Edn., Ed. Chow, S.C., Marcel Dekker, Inc., New York, pp. 934–939.
207. Nordbrock, E. (2009). Use of statistics to establish a stability trend: Matrixing. In: Pharmaceutical Testing to Support Global Markets. Kim Kuynh-Ba Ed. Springer, New York, 2009.
208. Nordbrock, E. and Valvani, S. (1995). PhRMA Stability Working Group. In: Guideline for Matrix Designs of Drug Product Stability Protocols, January 1995.
209. Owen, D.B. (1965). A special case of a noncentral t distribution. Biometrika, 52, 437–446.
210. Papadatos, N. (1995). Maximum variance of order statistics. Ann. Inst. Stat. Math, 47, l85–193.
211. Patel, H.I. (1994). Dose-response in pharmacokinetics. Comm. Stat. Theory Methods, 23, 451–465.
212. Phillips, K.F. (1990). Power of the two one-sided tests procedure in bioequivalence. J. Pharm. Biopharm., 18, 137–144.
213. Phillips, K.F. (2003). A new test of non-inferiority for anti-infective trials. Stat. Med., 22, 201–212.
214. PIC/S. (2009). Guide to Good Manufacturing Practice for Switzerland Annexes. Pharmaceutical Inspection Convention Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland.
215. Pitman, E.J.G. (1939). A note on normal correlation. Biometrika, 31, 9–12.
216. Pocock, S.J. (1983). Clinical Trials—A Practical Approach. John Wiley & Sons, New York.
217. Pong, A. and Raghavarao, D. (2000). Comparison of bracketing and matrixing designs for a two-year stability study, J. Biopharm. Stat., 10, 217–228.
218. Quan, H. and Shih, W.J. (1996). Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics, 52, 1195–1203.
219. Raines, L.J. (2002). Bad medicine: Why the generic drug regulatory paradigm is inapplicable to biotechnology products. Biolaw. Bus., 5, 6–13.
220. Rodda, B.E. and Davis, R.L. (1980). Determining the probability of an important difference in bioavailability. Clin. Pharmacol. Ther., 28, 247–252.
221. Roger, S.D. (2006). Biosimilars: How similar or dissimilar are they? Nephrology, 11, 341–346.
222. Roger, S.D. and Mikhail, A. (2007). Biosimilars: Opportunity or cause for concern? J. Pharm. Sci., 10, 405–410.
223. Sargent, D.F., Wieand, S., Haller, D.G. et al. (2005). Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies. J. Clin. Oncol., 23, 8864–8670.
224. Schall, R. and Luus, H.G. (1993). On population and individual bioequivalence. Stat. Med., 12, 1109–1124.
225. Schellekens, H. (2003). Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. Curr. Med. Res. Opin., 19, 433–434.
226. Schellekens, H. (2004). How similar do ‘biosimilar’ need to be? Nat. Biotechnol., 22, 1357–1359.
227. Schellekens, H. (2005). Follow-on biologics: Challenges of the “next generation.” Nephrol. Dial. Transplant., 20(Suppl 4), 31–36.
228. Schuirmann, D.J. (1981). On hypothesis testing to determine if the mean of a normal distribution is continued in a known interval. Biometrics, 37, 617.
229. Schuirmann, D.J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm., 15, 657–680.
230. Serfling, R.J. (1980). Approximation Theorems of Mathematical Statistics, John Wiley, New York.
231. 2. Pharm. Res., 15, 889–896.
232. Shah, V.P., Yacobi, A., Barr, W.H. et al. (1996). Evaluation of orally administered highly variable drugs and drug formulations. Pharm. Res., 13, 1590–1594.
233. Shao, J. and Chen, L. (1997). Prediction bounds for random shelf-lives. Stat. Med., 16, 1167–1173.
234. Shao, J. and Chow, S.C. (1994). Statistical inference in stability analysis. Biometrics, 50, 753–763.
235. Shao, J. and Chow, S.C. (2002). Reproducibility probability in clinical trials. Stat. Med., 21, 17727–1742.
236. Simoens, S., Verbeken, G., and Huys, I. (2011). Market access of biosimilars: Not only a cost issue. Oncologie, 13(5), 218–221.
237. Suh, S.K. and Park, Y. (2011). Regulatory guideline for biosimilar products in Korea. Biologicals, 39, 336–338.
238. SUPAC-IR. (1995). The United States Food and Drug Administration Guideline Immediate Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. Rockville, MD.
239. Ting, N., Burdick, R.K., Graybill, F.A., Jeyaratnam, S., and Lu, T.-F.C. (1990). Confidence intervals on linear combinations of variance components that are unrestricted in sign. J. Stat. Comput. Simul., 35, 135–143.
240. Torti, F. (2008). FDA response to house subcommittee on health. Letter to the House on biosimilar issues. FDA, Rockville, MD, September 2008.
241. Tothfalusi, L., Endrenyi, L., and Arieta, A.G. (2009). Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin. Pharmacokinet., 48, 725–743.
242. Tothfalusi, L., Endrenyi, L., Midha, K.K., Rawson, M.J., and Hubbard, J.W. (2001). Evaluation of the bioequivalence of highly variable drugs and drug products. Pharm. Res., 18, 728–733.
243. Tothfalusi, L., Speidl, S., and Endrenyi, L. (2008). Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br. J. Clin. Pharmacol., 65, 110–122.
244. Tothfalusi, L. and Endrenyi, L. (2003). Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm. Res., 20, 382–389.
245. Tse, S.K., Chang, J.Y., Su, W.L., Chow, S.C., Hsiung, C., and Lu, Q. (2006). Statistical quality control process for traditional Chinese medicine. J. Biopharm. Stat., 16, 861–874.
246. Tsong, Y., Chen, W.J., and Chen, C.W. (2008). ANCOVA approach for shelf life analysis of stability study of multiple factor designs. J. Biopharm. Stat., 13, 375–393.
247. Tsong, Y., Higgins, K., Wang, S.J., and Hung, H.M.J. (1999). An overview of equivalence testing—CDER reviewers’ perspective. Proceedings of the Biopharmaceutical Section of American Statistical Association, Alexandria, VA, pp. 214–219.
248. Tsou, H.H., Chien, T.Y., Liu, J.P., and Hsiao, C.F. (2011). A consistency approach to evaluation of bridging studies and multiregional trials. Stat. Med., 30, 2171–2186.
249. USP/NF XXI. (2000). United States Pharmacopeia 24 and National Formulary 19. United States Pharmacopeial Convention, Inc., Rockville, MD.
250. Wang, J. and Chow, S.C. (2012). On regulatory approval pathway of biosimilar products. Pharmaceuticals, 5, 353–368.
251. Wang, Y.M. and Chow, A.T. (2010). Development of biosimilars—Pharmacokinetic and pharmacodynamic considerations. J. Biopharm. Stat., 20, 46–61.
252. Webber, K.O. (2007). Biosimilars: Are we there yet? Proceedings of the Biosimilars 2007, George Washington University, Washington, DC.
253. WHO. (1992). World Health Organization technical report series, No. 822. Geneva, Switzerland.
254. WHO. (2005). World Health Organization draft revision on multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Geneva, Switzerland.
255. WHO. (2009). Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva, Switzerland.
256. WHO. (2010). Guideline for the production and control of specified starting materials. Geneva, Switzerland.
257. Wilcoxon, F. (1945). Individual comparisons by ranking methods. Biometrics, 1, 80–83.
258. Wolff, R. (2011). CMC requirements for biological products. Proceedings of the Workshop Sponsored by Korean Food and Drug Administration, Seoul, South Korea, June 1, 2011.
259. Woodcock, J. (2007). The FDA’s assessment of follow-on protein products: A historical perspective. Nat. Rev. Drug Discov., 6, 437–442.
260. Woodcock, J., Griffin, J., Behrman, R. et al. (2007). The FDA’s assessment of follow-on protein products: A historical perspective. Nat. Rev. Drug Discov., 6, 437–442.
261. Yang, J., Zhang, N., Chow, S.C., and Chi, E. (2013). An extended F-test for heterogeneity of variability in follow-on biological products. Stat. Med., 32, 415–423.
262. Zhang, N., Yang, J., Chow, S.C., Endrenyi, L., and Chi, E. (2013). Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics. Stat. Med., 32, 424–433.